Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: iron(III)-hexacyanoferrate(II)
Trade Name: Radiogardase
Date Designated: 05/01/2003
Orphan Designation: Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium
Orphan Designation Status: Designated/Approved
Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
Goerzallee 253
D-14167
Berlin
Germany

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: iron(III)-hexacyanoferrate(II)
Trade Name: Radiogardase
Marketing Approval Date: 10/02/2003
Approved Labeled Indication: Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination
Exclusivity End Date: 10/02/2010 
Exclusivity Protected Indication* :  
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-